SCHEMBL13577009

SCHEMBL13577009

Cc1cccc(N(C)S(=O)(=O)c2ccc(Cl)c(N)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ PKM P14618 2/20 0.51
▸ GNRHR P30968 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ CA12 O43570 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ HSD17B1 P14061 3/20 0.45
▸ HSD17B2 P37059 3/20 0.45
▸ MAPT P10636 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ PAX8 Q06710 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13577005 0.88 PGR (0.49) ALDH1A1CYP3A4CYP2C9HPGDCYP2C19
SCHEMBL5467219 0.86 KDM4E (0.56) ALDH1A1POLBCA12CA9LMNA
SCHEMBL13577037 0.85 PSEN1 (0.46) ALDH1A1CYP3A4CYP2C9HPGDCYP2C19
SCHEMBL13577036 0.83 PGR (0.52) ALDH1A1LMNAHSD17B1HSD17B2KDM4E
SCHEMBL13577029 0.83 MAPT (0.44) ALDH1A1HSD17B1HSD17B2MAPTKDM4E
SCHEMBL25920658 0.81 ALDH1A1 (0.59) ALDH1A1CYP3A4CYP2C9HPGDCYP2C19
SCHEMBL17174228 0.81 LMNA (0.66) ALDH1A1CYP3A4CYP2C9HPGDCYP2C19
SCHEMBL13577030 0.80 PGR (0.52) ALDH1A1HPGDHSD17B10CA12CA9
SCHEMBL10300188 0.80 ESR1 (0.41) ALDH1A1PKMPOLBLMNAMAPT
SCHEMBL10300185 0.79 C5AR1 (0.47) ALDH1A1MAPTKDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040693-B2 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 — — US disclosed
US-9040693-B2 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 — — US disclosed
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 — — US disclosed
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF SHBG, CYP19A1, NR5A1 ALDH1A1 1048/4885CYP3A4 288/4885CYP2C9 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback